Vericel Co. (NASDAQ:VCEL) Insider Sells $304,875.44 in Stock

Vericel Co. (NASDAQ:VCEL) insider Sean C. Flynn sold 6,772 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $45.02, for a total value of $304,875.44. Following the transaction, the insider now owns 487 shares in the company, valued at approximately $21,924.74. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Vericel Stock Performance

VCEL stock traded up $1.19 during trading on Monday, hitting $46.19. The company had a trading volume of 473,154 shares, compared to its average volume of 495,781. The business has a 50-day moving average of $46.59 and a 200-day moving average of $44.22. Vericel Co. has a one year low of $30.18 and a one year high of $53.05.

Vericel (NASDAQ:VCEL) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The business had revenue of $51.28 million for the quarter, compared to analysts’ expectations of $49.07 million. During the same period in the prior year, the business posted ($0.16) earnings per share. The firm’s revenue was up 25.0% on a year-over-year basis. As a group, research analysts forecast that Vericel Co. will post 0.09 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on VCEL shares. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Friday. TD Cowen started coverage on Vericel in a research report on Thursday. They set a “buy” rating and a $55.00 price objective on the stock. Truist Financial reiterated a “buy” rating and set a $54.00 price objective on shares of Vericel in a research report on Tuesday, March 26th. Finally, HC Wainwright raised their price target on Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.17.

Hedge Funds Weigh In On Vericel

Institutional investors have recently modified their holdings of the company. Knights of Columbus Asset Advisors LLC raised its position in shares of Vericel by 98.5% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 226,015 shares of the biotechnology company’s stock worth $8,048,000 after purchasing an additional 112,169 shares during the period. Federated Hermes Inc. raised its position in Vericel by 21.2% in the 4th quarter. Federated Hermes Inc. now owns 560,419 shares of the biotechnology company’s stock valued at $19,957,000 after buying an additional 97,952 shares during the last quarter. Geneva Capital Management LLC raised its position in Vericel by 8.7% in the 4th quarter. Geneva Capital Management LLC now owns 472,963 shares of the biotechnology company’s stock valued at $16,842,000 after buying an additional 37,784 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Vericel by 54.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 126,383 shares of the biotechnology company’s stock valued at $4,236,000 after purchasing an additional 44,507 shares during the period. Finally, Legato Capital Management LLC grew its stake in Vericel by 20.6% in the 4th quarter. Legato Capital Management LLC now owns 10,340 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 1,765 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.